Myeloproliferative neoplasm causes: Difference between revisions

	Myeloproliferative Neoplasm Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating myeloproliferative neoplasm from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myeloproliferative neoplasm causes On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myeloproliferative neoplasm causes All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myeloproliferative neoplasm causes
on Myeloproliferative neoplasm causes
Myeloproliferative neoplasm causes in the news
Blogs on Myeloproliferative neoplasm causes
Directions to Hospitals Treating Myeloproliferative neoplasm
Risk calculators and risk factors for Myeloproliferative neoplasm causes

VisualWikitext

Latest revision as of 22:48, 12 July 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]

Overview

Myeloproliferative neoplasm is caused by mutations in various genes. Different gene mutations are responsible for each of the 8 subtypes of myeloproliferative neoplasms.^[1]

Causes


Myeloproliferative neoplasm subtype	Causative gene mutation

Polycythemia vera	JAK2 V617F in 95% of cases^[2] CALR MPL
Essential thrombocythemia	JAK2 V617F in 50-60% of cases^[3] CALR MPL
Primary myelofibrosis	JAK2 V617F in 50-60% of cases^[4] CALR MPL
Chronic myeloid leukemia	BCR-ABL SETBP1 in atypical CML^[5]
Chronic neutrophilic leukemia	CSF3R^[6] SETBP1 in rare cases
Chronic eosinophilic leukemia	FIP1L1-PDGFRA^[7] PDGFRB^[7] FGFR1^[7] PCM1-JAK2
Myeloproliferative neoplasm, unclassifiable	Variable
Mastocytosis	c-kit D816V^[8]

References

↑ Ganfyd. Polycythaemia vera 2015.http://www.ganfyd.org/index.php?title=Polycythemia_vera
↑ Griesshammer M, Gisslinger H, Mesa R (2015). "Current and future treatment options for polycythemia vera". Ann Hematol. 94 (6): 901–10. doi:10.1007/s00277-015-2357-4. PMC 4420843. PMID 25832853.
↑ Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F; et al. (2010). "Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia". Haematologica. 95 (8): 1435–8. doi:10.3324/haematol.2009.021444. PMC 2913097. PMID 20418246.
↑ Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I; et al. (2014). "Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis". Blood. 124 (7): 1062–9. doi:10.1182/blood-2014-05-578435. PMC 4133481. PMID 24986690.
↑ Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A; et al. (2013). "Recurrent SETBP1 mutations in atypical chronic myeloid leukemia". Nat Genet. 45 (1): 18–24. doi:10.1038/ng.2495. PMC 3588142. PMID 23222956.
↑ Szuber N, Tefferi A (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer J. 8 (2): 19. doi:10.1038/s41408-018-0049-8. PMC 5811432. PMID 29440636.
↑ ^7.0 ^7.1 ^7.2 Falchi L, Verstovsek S (2015). "Eosinophilia in Hematologic Disorders". Immunol Allergy Clin North Am. 35 (3): 439–52. doi:10.1016/j.iac.2015.04.004. PMC 4515577. PMID 26209894.
↑ Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O; et al. (2017). "Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future". Cancer Res. 77 (6): 1261–1270. doi:10.1158/0008-5472.CAN-16-2234. PMC 5354959. PMID 28254862.

Template:WH Template:WS

[ganfyd-1] Ganfyd. Polycythaemia vera 2015.http://www.ganfyd.org/index.php?title=Polycythemia_vera

[pmid25832853-2] Griesshammer M, Gisslinger H, Mesa R (2015). "Current and future treatment options for polycythemia vera". Ann Hematol. 94 (6): 901–10. doi:10.1007/s00277-015-2357-4. PMC 4420843. PMID 25832853.

[pmid20418246-3] Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F; et al. (2010). "Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia". Haematologica. 95 (8): 1435–8. doi:10.3324/haematol.2009.021444. PMC 2913097. PMID 20418246.

[pmid24986690-4] Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I; et al. (2014). "Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis". Blood. 124 (7): 1062–9. doi:10.1182/blood-2014-05-578435. PMC 4133481. PMID 24986690.

[pmid23222956-5] Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A; et al. (2013). "Recurrent SETBP1 mutations in atypical chronic myeloid leukemia". Nat Genet. 45 (1): 18–24. doi:10.1038/ng.2495. PMC 3588142. PMID 23222956.

[pmid29440636-6] Szuber N, Tefferi A (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer J. 8 (2): 19. doi:10.1038/s41408-018-0049-8. PMC 5811432. PMID 29440636.

[pmid26209894-7] 7.0 ^7.1 ^7.2 Falchi L, Verstovsek S (2015). "Eosinophilia in Hematologic Disorders". Immunol Allergy Clin North Am. 35 (3): 439–52. doi:10.1016/j.iac.2015.04.004. PMC 4515577. PMID 26209894.

[pmid28254862-8] Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O; et al. (2017). "Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future". Cancer Res. 77 (6): 1261–1270. doi:10.1158/0008-5472.CAN-16-2234. PMC 5354959. PMID 28254862.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

@@ Line 3: / Line 3: @@
 {{CMG}}{{AE}} {{MJK}} {{shyam}}
 ==Overview==
-Myeloproliferative neoplasm is caused by mutations in various genes. Different gene mutations are responsible for each of the 8 subtypes of myeloproliferative neoplasms. <ref name="ganfyd">Ganfyd. Polycythaemia vera 2015.http://www.ganfyd.org/index.php?title=Polycythemia_vera</ref><ref name="pmidhttp://dx.doi.org/10.1182/blood-2013-11-538983">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=http://dx.doi.org/10.1182/blood-2013-11-538983 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10  }} </ref><ref name="ganfyd">Ganfyd. Myelofibrosis2015.http://www.ganfyd.org/index.php?title=Primary_myelofibrosis</ref>
+Myeloproliferative neoplasm is caused by mutations in various genes. Different gene mutations are responsible for each of the 8 subtypes of myeloproliferative neoplasms.<ref name="ganfyd">Ganfyd. Polycythaemia vera 2015.http://www.ganfyd.org/index.php?title=Polycythemia_vera</ref>
 ==Causes==
@@ Line 13: / Line 13: @@
 |-
 | style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |
-Polycythemia vera
+[[Polycythemia vera]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
-*''JAK2'' ''V617F'' in 95% of cases
+*''JAK2'' ''V617F'' in 95% of cases<ref name="pmid25832853">{{cite journal| author=Griesshammer M, Gisslinger H, Mesa R| title=Current and future treatment options for polycythemia vera. | journal=Ann Hematol | year= 2015 | volume= 94 | issue= 6 | pages= 901-10 | pmid=25832853 | doi=10.1007/s00277-015-2357-4 | pmc=4420843 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25832853  }} </ref>
 *''CALR''
 *''MPL''
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
-Essential thrombocythemia
+[[Essential thrombocythemia]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
 *''JAK2'' ''V617F'' in 50-60% of cases<ref name="pmid20418246">{{cite journal| author=Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F et al.| title=Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. | journal=Haematologica | year= 2010 | volume= 95 | issue= 8 | pages= 1435-8 | pmid=20418246 | doi=10.3324/haematol.2009.021444 | pmc=2913097 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20418246  }} </ref>
@@ Line 27: / Line 27: @@
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
-Primary myelofibrosis
+[[Primary myelofibrosis]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
-*''JAK2'' ''V617F'' in 50-60% of cases
+*''JAK2'' ''V617F'' in 50-60% of cases<ref name="pmid24986690">{{cite journal| author=Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martínez-Trillos A, Casetti I et al.| title=Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. | journal=Blood | year= 2014 | volume= 124 | issue= 7 | pages= 1062-9 | pmid=24986690 | doi=10.1182/blood-2014-05-578435 | pmc=4133481 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24986690  }} </ref>
 *''CALR''
 *''MPL''
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
-Chronic myeloid leukemia
+[[Chronic myeloid leukemia]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
 *''BCR-ABL''
@@ Line 40: / Line 40: @@
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
-Chronic neutrophilic leukemia
+[[Chronic neutrophilic leukemia]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
 *''CSF3R''<ref name="pmid29440636">{{cite journal| author=Szuber N, Tefferi A| title=Chronic neutrophilic leukemia: new science and new diagnostic criteria. | journal=Blood Cancer J | year= 2018 | volume= 8 | issue= 2 | pages= 19 | pmid=29440636 | doi=10.1038/s41408-018-0049-8 | pmc=5811432 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29440636  }} </ref>
@@ Line 46: / Line 46: @@
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
-Chronic eosinophilic leukemia
+[[Chronic eosinophilic leukemia]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
 *''FIP1L1-PDGFRA''<ref name="pmid26209894">{{cite journal| author=Falchi L, Verstovsek S| title=Eosinophilia in Hematologic Disorders. | journal=Immunol Allergy Clin North Am | year= 2015 | volume= 35 | issue= 3 | pages= 439-52 | pmid=26209894 | doi=10.1016/j.iac.2015.04.004 | pmc=4515577 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26209894  }} </ref>
@@ Line 54: / Line 54: @@
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
-Myeloproliferative neoplasm, unclassifiable
+[[Myeloproliferative neoplasm, unclassifiable]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
 *Variable
 |-
 | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |
-Mastocytosis
+[[Mastocytosis]]
 | style="padding: 5px 5px; background: #F5F5F5;" |
-*''c-kit'' ''D816V''
+*''c-kit'' ''D816V''<ref name="pmid28254862">{{cite journal| author=Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O et al.| title=Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. | journal=Cancer Res | year= 2017 | volume= 77 | issue= 6 | pages= 1261-1270 | pmid=28254862 | doi=10.1158/0008-5472.CAN-16-2234 | pmc=5354959 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28254862  }} </ref>
 |}

Myeloproliferative neoplasm causes: Difference between revisions

Latest revision as of 22:48, 12 July 2018

Overview

Causes

References

Navigation menu